Views:0 Author:Site Editor Publish Time: 2021-01-26 Origin:Site
Amphotericin B (AMPH) has been used as a standard drug for the treatment of deep mycosis for about 40 years since it was put on sale in the 1960s.
After that, Floconazole (FLCZ) was launched in 1989 and Itraconazore (ITCZ) was launched in 1993. Great progress has been made in the treatment of deep mycosis. However, these drugs, due to antifungal spectrum or drug type problems, are still not enough. Moreover, with the progress of medicine, the improvement of the prognosis of patients with low immune ability such as hematological malignancies, and other patients with severe systemic conditions, resulting in the significant increase of susceptible hosts, has brought new threats to the treatment of deep mycosis. For example, the mortality rate of invasive aspergillosis is about 58% , and the mortality rate of cerebral aspergillosis is close to 100%. In response to these new threats, Voriconazole (VRCZ) was developed by Pfizer's Sandwich Institute in the UK.
Dosage forms of VRCZ
In the treatment of deep mycosis, due to the poor state of the whole body, many cases can not be taken orally, many cases need early treatment effect, so the necessity of injection is very high. On the other hand, because the treatment period can reach more than a few months, oral administration is also needed. At present,there are two types of oral administration and injection in China. Oral administration has a high absorption rate. The only antifungal drug that can be used equally in oral administration and injection is FLCZ.
There are two types of VRCZ: oral and injection. The oral is stable and the absorption rate is close to 100%. In order to improve the solubility of vrcz,Sulfobutyl-β-cyclodextrin sodium(SBECD) was added into the injection as the main excipient.
Shandong Binzhou Zhiyuan biology began to develop and produce Sulfobutyl-β-cyclodextrin sodium(SBECD) in 2012, and obtained FDA certification in 2015. SBECD have been exported to the United States, Europe, India, Pakistan and other overseas markets, and in terms of product stability and endotoxin control, have been highly praised by customers.
At present, Shandong Binzhou Zhiyuan is jointly applying for voriconazole products with a number of Chinese pharmaceutical factories, striving to provide stable quality SBECD products for the Chinese pharmaceutical market, and contributing to the successful listing of VRCZ products in the Chinese market.